MedWatch

Analysts to home in on expenses in Genmab's Wednesday fiscal report

Analysts are awaiting Genmab's fiscal report with anticipation, not due to the sales figures for Darzalex and Kesimpta, but because of expenses.

Photo: Tuala Hjarnø / Genmab / PR

Analysts will be homing in on listed expenses when Genmab publishes its fiscal report for the first three months of the year on Wednesday afternoon after the stock exchange closes.

When it comes to the firm's revenue, most of the relevant considerations have already been revealed. In April, Genmab's partner Johnson & Johnson reported selling Darzalex for USD 1.365bn which was a better price than expected.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs